Pruritus, commonly known as itching, is a distressing symptom often experienced by dermatitis patients. Dermatitis is an inflammatory skin condition characterized by redness, rash, and irritation. The persistent itch can lead to scratching, exacerbating the skin's inflammation. This cycle of scratching and inflammation can worsen the condition and lead to skin damage. Treatment options for pruritus in dermatitis patients include topical corticosteroids, antihistamines, and moisturizers to alleviate symptoms. Identifying triggers, such as allergens or irritants, is crucial for effective management. Patients should refrain from scratching, maintain good skincare practices, and seek medical advice to minimize discomfort and improve their quality of life.
Clinical TrialRuxolitinib cream is a topical medication containing ruxolitinib, an inhibitor of Janus kinases 1 and 2 (JAK1/JAK2). A clinical trial investigated the effects of ruxolitinib cream on itch in patients with atopic dermatitis (AD), a skin condition known for its intense itching and inflammation.
The research involved two phase 3 trials, TRuE-AD1 and TRuE-AD2, which enrolled 1249 patients aged 12 years and above, suffering from AD for at least two years, with an Investigator's Global Assessment score of 2 or 3, and 3%-20% of the body surface affected. The participants were randomly assigned to apply 0.75% ruxolitinib cream, 1.5% ruxolitinib cream, or a vehicle cream twice daily for eight weeks in a double-blinded treatment.